The Chicago-based, physician-led platform combines AI-driven diagnostics, clinical automation and longevity science across fertility care. The round, co-led by ARTIS and Humania, will fund expansion of US clinical operations and entry into the Gulf Cooperation Council region, backed by Humania's network of 18 tertiary hospitals across the Gulf and North Africa.
“ONTO was built to meet people where they are and to stay with them as their needs evolve. Fertility care has often been too narrowly focused. We view reproductive care as part of a broader, lifelong health journey rather than a single episode of treatment, and are dedicated to a comprehensive, human-centered approach to both." — Dr. Roohi Jeelani, CEO & Co-Founder, ONTO Health
🔗 https://sg.finance.yahoo.com/news/ai-enabled-fertility-care-longevity-115200723.html
India-based Sun Pharmaceutical Industries has reportedly submitted an offer to fully acquire Organon & Co. in an all-cash transaction, sending shares up 38.8% week-on-week. Neither company has confirmed or denied the reports. Organon, spun off from Merck in 2021, focuses on reproductive health, women's health and contraception.
“Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide. Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. We are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients.” — Alex Albert, Partner & Co-Head of Healthcare, TPG Capital
🔗 https://www.insidermonkey.com/blog/organon-ogn-climbs-39-on-12-billion-merger-buzz-1736437/?amp=1
The round, led by Ambit Health Ventures with participation from Emmeline Ventures and Disrupt Health Impact Fund, will scale manufacturing and broaden commercialization of Osteoboost's Class II prescription device. Worn around the hips, it delivers low-magnitude vibration therapy based on NASA-originated research - reducing bone density loss by 85% in the spine and 55% in the hips in a 12-month clinical trial. The device has been prescribed by more than 2,500 physicians across 30+ academic medical centres.
“For years, when a patient with osteopenia asked what they could do beyond calcium, vitamin D and exercise, we didn’t have much to offer. The availability of the FDA-approved Osteoboost device provides a clinically supported, non-drug option that allows us to intervene earlier.” — David B. Karpf, Endocrinologist, Stanford University School of Medicine
🔗 https://www.medicaleconomics.com/view/osteoboost-raises-8m-to-expand-reach-of-bone-density-device
Developed at Yale, Wavelet's non-invasive fetal EEG platform detects neurological distress in real time through the mother's abdomen without scalp electrodes. The $7M seed, backed by Aegis Ventures, targets a significant clinical gap: fetal heart rate monitoring is indeterminate in up to 85% of births, contributing to missed hypoxia cases and unnecessary C-sections. The company is currently in trials at three clinical sites.
"This is the moment breakthrough science becomes scalable impact. Aegis brings the ecosystem, experience, and capital needed to accelerate product development, clinical adoption, and commercialization. Together, we have a real opportunity to redefine what 'standard of care' means in fetal medicine - and to save lives." — Liz Golden CEO & Founder, Aegis Ventures
Waters has received FDA clearance for an at-home cervical cancer screening kit, designed for use with BD's Onclarity HPV assay to detect all high-risk HPV types. Patients collect a sample at home and mail it to a laboratory, with results shared with their healthcare provider. Around 60% of cervical cancers occur in people who are not screened or screened less frequently than recommended.
"Cancer vaccines are a new class of treatment seeing promising results in early studies. We are at a pivotal moment for this research. Trials like this and the partnerships that CVC is building, are designed to help bring groundbreaking therapies to patients sooner." — Kristen Dahlgren, Founder & CEO, Cancer Vaccine Coalition "At TMRW, our mission has always been to safeguard life's most precious cells and advance the standard of care. By joining forces with Reprotech, we have the opportunity to bring together trusted infrastructure, national scale, and digital innovation in a way that is truly differentiated in the fertility market. I'm excited to lead this next chapter and help build the future of fertility cryostorage." — Louis Villalba, Chief Executive Officer, TMRW
The UK government's renewed Women's Health Strategy includes a £1.5M FemTech challenge fund to accelerate adoption of innovations in women's healthcare, alongside plans to streamline gynaecological pathways for conditions including endometriosis and fibroids. The strategy also commits to new pain relief standards for invasive gynaecological procedures, with endometriosis diagnosis times currently averaging nine years and four months.
“The renewed women’s health strategy will build significantly on the work the NHS has been doing to ensure women are heard and get the specialist care they need – with a focus on bringing down waiting times, delivering more care in communities, and giving women more choice over their care.” — Dr Sue Mann, Clinical Director for Women’s Health, NHS England
🔗 https://www.digitalhealth.net/2026/04/1-5m-femtech-fund-launched-under-womens-health-strategy/
